GLP-1s Are a Lot Weirder Than Anyone Thought | The Ezra Klein Show

Here’s a shocking number: One out of eight American adults is taking a GLP-1, like Ozempic or Zepbound, according to a KFF poll. GLP-1s are the biggest pharmaceutical story since antidepressants. But there's still so much we don't know. “We're only at the beginning of what's been called this Ozempic era,” the journalist Julia Belluz told me. “I think we're really just at the beginning of discovering the benefits and the harms of these drugs.” These discoveries begin in the research but are also expanding into how we think about our punishing beauty standards and the blurry lines between illness and wellness. Belluz is a contributing Opinion writer and the -author, with Kevin Hall, of “Food Intelligence.” She’s one of the best health and science reporters I know and has been reporting on GLP-1s for years. In this conversation, Belluz takes me through what we know — and don’t know — about GLP-1s, their unexpected uses, how they are clashing with a culture obsessed with thinness and looksmaxxing, and whether everyone should be on them. Read the full transcript here: https://www.nytimes.com/2026/05/08/opinion/ezra-klein-podcast-julia-belluz.html Watch more on @EzraKleinShow Thoughts? Guest suggestions? Email us at ezrakleinshow@nytimes.com. You can find transcripts (posted midday) and more episodes of “The Ezra Klein Show” at nytimes.com/ezra-klein-podcast. Book recommendations from all our guests are listed at https://www.nytimes.com/article/ezra-klein-show-book-recs.html